β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma
about
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancerβ1 and β4 integrins: from breast development to clinical practiceComputational identification of epigenetically regulated lncRNAs and their associated genes based on integrating genomic data.Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysisMacrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma ModelMesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomasThe future of high-grade glioma: Where we are and where are we going.Expression of galectin-1 in carcinoma-associated fibroblasts promotes gastric cancer cell invasion through upregulation of integrin β1.Two of Them Do It Better: Novel Serum Biomarkers Improve Autoimmune Hepatitis Diagnosis.mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking β1 integrin activation.STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma.Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway.Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling.Bevacizumab for glioblastoma: current indications, surgical implications, and future directionsPrognostic value of β1 integrin expression in colorectal liver metastasesSuppression of Eosinophil Integrins Prevents Remodeling of Airway Smooth Muscle in Asthma.GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.Integrin modulators: a patent review.Resistance to antiangiogenic therapy.Current evidence of temozolomide and bevacizumab in treatment of gliomas.Molecularly targeted therapies for recurrent glioblastoma: current and future targets.Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy.Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic TargetingIdentification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.Molecular Targeting of Integrins and Integrin-Associated Signaling Networks in Radiation Oncology.Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas.Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas.Glioblastoma in natalizumab-treated multiple sclerosis patients.The Microvascular Gap Junction Channel: A Route to Deliver MicroRNAs for Neurological Disease TreatmentAdhesion- and stress-related adaptation of glioma radiochemoresistance is circumvented by β1 integrin/JNK co-targeting.Targeting the Cohesive Cluster Phenotype in Chordoma via β1 Integrin Increases Ionizing Radiation Efficacy.Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy.Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.
P2860
Q26774789-2B17B037-FCC0-4344-9183-8C42227E5B67Q27000311-6CE4A43A-7873-4B40-948C-A65B9FBD5F44Q30885763-65774B5B-C3B4-47F6-BC62-F787FAC0FBADQ31125309-2560B0DD-E207-4CD8-BCF8-591F219B12E0Q33853991-285B2BB8-D330-47C6-BF82-3B80C07A4C6CQ34044274-791986BE-7B38-418E-8F12-FAEE9B5CC376Q34311697-54A0F3DB-4A25-40D2-B855-F55F7D2EFAD4Q34347733-DC3A8E14-B54A-4456-B97A-61757EF42F8FQ34807753-49F166E5-794A-4582-A19B-743C55E82F31Q35114090-3E503CF6-2BC5-4111-AAC5-99DAB1EAC8D4Q35713332-3965EB36-A315-40AE-B888-1638BFD3CE01Q35777077-9DBDE2E7-676F-4F2C-84C6-C82C46145116Q35921941-5E93D407-C97B-4212-917F-B2306BF713F3Q36070842-5FA69683-7759-4DDF-B61E-29D671E705E6Q36140675-E8B6E73F-327A-4931-843E-7D6757186ED1Q36172612-50313A7A-69E9-4C84-B83C-46241D8716F7Q36413742-BE5DEEBE-6FD4-4ACF-B301-72C6D40F7F46Q36592509-F492E143-AA67-40F4-A146-46C6F4131BC8Q36785112-604F1F90-96A6-4694-984B-36AC2955F2D3Q36822207-2B9723FE-A2CA-4B1A-8923-8F0D87708CF0Q37452274-32AB2358-AD7A-4997-9FD2-43389F0C79DCQ37570406-BD29552E-1B49-49DA-ACE4-4EE5EA44C28FQ37599547-CCDC43B8-B561-4717-AB24-F0D99B2F89F1Q38139612-863DE74B-EF74-480A-8779-DAE47E8F4F49Q38197943-93A7A70F-4C61-4C96-95E5-50CD6BCE5074Q38230650-7F9B1095-7218-4702-A180-D5A742B0CC03Q38272728-2BDE1D51-FC7C-4146-B643-FA03BC2B4382Q38599484-2739F717-A9DD-4EAB-9418-E061AE929570Q38736395-01B62F1A-2855-46F0-A44B-1AEF661688DBQ38822335-8B2EF533-F53C-41C5-A17F-6032061936D3Q38869424-A9D17933-128C-457B-8F37-EDC7C2B3AF60Q38958545-7A6EBBC6-513B-4A1D-8729-30135DE49722Q38989530-1FBD83CC-5E4B-44B1-B333-0CE17AD521FCQ39174318-762619D1-F507-4A95-90DD-DB0ECD223F3BQ40128064-9546BF99-375E-4E2E-BAF1-FB1D06CBAFACQ41243197-85CC36FE-9875-4379-9093-036ECD9DB7EDQ41472395-D00E33B4-35F1-41A3-A964-BB6CFC8E6197Q41989354-3E88DA7E-9290-487D-AE45-D60600AA824CQ42362586-31124EA0-0C8C-42CD-90C6-7A1C6C9E08C6Q44411444-0553FD91-061B-4DFC-930F-347527D5FC9F
P2860
β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
β1 integrin targeting potentia ...... cizumab-resistant glioblastoma
@ast
β1 integrin targeting potentia ...... cizumab-resistant glioblastoma
@en
β1 integrin targeting potentia ...... cizumab-resistant glioblastoma
@nl
type
label
β1 integrin targeting potentia ...... cizumab-resistant glioblastoma
@ast
β1 integrin targeting potentia ...... cizumab-resistant glioblastoma
@en
β1 integrin targeting potentia ...... cizumab-resistant glioblastoma
@nl
prefLabel
β1 integrin targeting potentia ...... cizumab-resistant glioblastoma
@ast
β1 integrin targeting potentia ...... cizumab-resistant glioblastoma
@en
β1 integrin targeting potentia ...... cizumab-resistant glioblastoma
@nl
P2093
P2860
P3181
P1433
P1476
β1 integrin targeting potentia ...... cizumab-resistant glioblastoma
@en
P2093
Arman Jahangiri
Catherine C Park
Manish K Aghi
Michael DeLay
W Shawn Carbonell
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-13-0011
P407
P577
2013-05-15T00:00:00Z